A

Alexion

Global biopharmaceuticals focusing on rare diseases

Director Head of Quality Management Systems & Smart Release

Regulatory & Quality (Life Sciences)Updated on Nov 14
Full-timeNo salary listed

About the Job

Requirements

  • A degree in pharmacy, science, engineering, or a related discipline is required; an advanced degree is preferred.
  • Extensive senior Quality leadership experience in a global, highly regulated biopharmaceutical setting is required.
  • Proven leadership of global Quality Systems and Complaints, including regulatory inspections, is required.
  • Experience leading a comparable shift involving global process simplification or release redesign through a matrix is required.
  • Technical expertise in QMS, complaints, risk management, CAPA, change control, data integrity, and end-to-end disposition and release across manufacturing, testing, and external supply is required.
  • Data and AI fluency sufficient to shape use cases and challenge AI outputs is required.

Responsibilities

  • Own the Smart Release vision, target process, roadmap, business case, and benefits as part of the integrated Future Quality 2030 transformation roadmap.
  • Translate customer and Quality Operations needs into prioritised process, data, technology, and control requirements, and lead redesign and adoption with affected teams while team leaders remain accountable for compliant execution in their areas.
  • Track release cycle time, right-first-time, exception resolution, capacity, and supply reliability benefits, and prioritise further simplification and automation based on risk and value.
  • Own and continuously improve the operating model of QMS and Smart Release.
  • Own the global QMS for the Rare Disease Unit and its core processes, including deviations and quality events, CAPA, change control, documentation, training, SAP Quality inputs, complaints, and Quality Risk Management.
  • Lead Quality Management Review and Annual Product Quality Review, ensuring each site operates against global requirements.
  • Set global process standards with clear process owners, local responsibilities, and escalation routes; simplify and harmonise processes across the network.
  • Lead the Digital QMS programme to make Quality workflows simpler and digital for every team.
  • Advance Quality Management Maturity in line with ICH Q10 and modernise Quality Risk Management in line with ICH Q9(R1), linking risk, evidence, and decisions clearly.
  • Build knowledge management and leading indicators so lessons are captured, reused, and acted on earlier.
  • Redesign work so that AI increasingly handles evidence gathering, classification, and routing while experts focus on judgement.
  • Work with Quality Data and Digital & AI Assurance, which independently assures data, systems, and AI for their intended use.
  • Feed Quality system and release performance into the function-wide view of performance.
  • Lead inspection and audit support for QMS and Smart Release, escalate systemic Quality risks, and drive timely, effective closure of commitments.
  • Apply data-integrity requirements to data created by QMS, Complaints, and release processes.
  • Lead and develop a global team of Quality Systems professionals and process owners, building succession, AI-enabled skills, and a culture of continuous improvement.

About the Company

Alexion

Global biopharmaceuticals focusing on rare diseases

Alexion, now the rare disease group within AstraZeneca, develops and sells therapies for rare and ultra-rare diseases by targeting the complement immune system. Its drugs, such as Soliris and Ultomiris, inhibit the C5 component to slow or stop disease processes, while Strensiq and Kanuma address specific metabolic disorders. It differentiates itself through a deep focus on complement biology, pursuing first- or best-in-class therapies, and using a strategy that blends internal R&D with acquisitions to expand its pipeline. Its goal is to improve outcomes for patients with rare diseases and bring these therapies to a broader international market using AstraZeneca’s scale and capabilities.

Company size
5,001-10,000
Company stage
IPO
Headquarters
Boston, MA
Founded
1992

Recently Posted Jobs

Explore more opportunities at Alexion

See more jobs